Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.32 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.32 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.32 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.31 |
| ▸ | PNMT | P11086 | 5/20 | 0.38 |
| ▸ | ADCY6 | O43306 | 1/20 | 0.35 |
| ▸ | ADCY3 | O60266 | 1/20 | 0.35 |
| ▸ | ADCY9 | O60503 | 1/20 | 0.35 |
| ▸ | ADCY5 | O95622 | 1/20 | 0.35 |
| ▸ | ADCY8 | P40145 | 1/20 | 0.35 |
| ▸ | ADCY7 | P51828 | 1/20 | 0.35 |
| ▸ | ADCY2 | Q08462 | 1/20 | 0.35 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.35 |
| ▸ | ADCY4 | Q8NFM4 | 1/20 | 0.35 |
| ▸ | NISCH | Q9Y2I1 | 2/20 | 0.32 |
| ▸ | HTR7 | P34969 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18920124 | 0.98 | PNMT (0.39) | PNMTADCY6ADCY3ADCY9ADCY5 | |
| SCHEMBL17462475 | 0.77 | PNMT (0.37) | PNMTADCY6ADCY3ADCY9ADCY5 | |
| SCHEMBL9507295 | 0.74 | ACHE (0.40) | LMNACYP1A2CYP2D6ALOX15HSD17B10 | |
| SCHEMBL16518067 | 0.74 | PNMT (0.40) | PNMTNISCHADRA2AADRA2BADRA2C | |
| SCHEMBL18920026 | 0.74 | PNMT (0.41) | PNMTNISCHADRA2AADRA2BADRA2C | |
| Bromide SCHEMBL15515105 | 0.71 | PNMT (0.47) | PNMTADCY6ADCY3ADCY9ADCY5 | |
| SCHEMBL20209031 | 0.70 | ERN1 (0.48) | LMNATSHRHSD17B10ERN1KDM4E | |
| SCHEMBL6314154 | 0.70 | KDM4E (0.36) | LMNACYP1A2CYP2D6ALOX15HSD17B10 | |
| SCHEMBL11981382 | 0.70 | HTR2C (0.44) | PNMTNISCHADRA2AADRA2BADRA2C | |
| SCHEMBL3057424 | 0.69 | CD44 (0.44) | PNMTADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180334436-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES | VIIV HEALTHCARE UK LIMITED (GB) | 2018-11-22 | — | — | US | disclosed |
| EP-3383866-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES | ViiV Healthcare UK Limited (GB) | 2018-10-10 | — | — | EP | disclosed |
| WO-2017093938-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES | VIIV HEALTHCARE UK LIMITED (GB) | 2017-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180334436-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES | MAVS, EIF2AK2, SARS1 | ADRA2A 2199/4885ADRA2B 1538/4885ADRA2C 909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.